Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of novel therapeutic targets for blocking acantholysis in pemphigus.
Burmester IAK, Flaswinkel S, Thies CS, Kasprick A, Kamaguchi M, Bumiller-Bini V, Emtenani S, Feldmann N, Kridin K, Schmidt E, van Beek N, Zillikens D, Hammers CM, Hundt JE, Ludwig RJ. Burmester IAK, et al. Among authors: kamaguchi m. Br J Pharmacol. 2020 Nov;177(22):5114-5130. doi: 10.1111/bph.15233. Epub 2020 Sep 21. Br J Pharmacol. 2020. PMID: 32815159 Free PMC article.
Immunoglobulin M pemphigoid.
Boch K, Hammers CM, Goletz S, Kamaguchi M, Ludwig RJ, Schneider SW, Zillikens D, Hadaschik E, Schmidt E. Boch K, et al. Among authors: kamaguchi m. J Am Acad Dermatol. 2021 Dec;85(6):1486-1492. doi: 10.1016/j.jaad.2021.01.017. Epub 2021 Jan 13. J Am Acad Dermatol. 2021. PMID: 33453342
Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases.
Ghorbanalipoor S, Emtenani S, Parker M, Kamaguchi M, Osterloh C, Pigors M, Gross N, Khil'chenko S, Kasprick A, Patzelt S, Wortmann D, Ibrahim IO, Izumi K, Goletz S, Boch K, Kalies K, Bieber K, Smith P, Schmidt E, Ludwig RJ. Ghorbanalipoor S, et al. Among authors: kamaguchi m. Front Immunol. 2022 Sep 28;13:865241. doi: 10.3389/fimmu.2022.865241. eCollection 2022. Front Immunol. 2022. PMID: 36248903 Free PMC article.
Corrigendum: Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases.
Ghorbanalipoor S, Emtenani S, Parker M, Kamaguchi M, Osterloh C, Pigors M, Gross N, Khil'chenko S, Kasprick A, Patzelt S, Wortmann D, Ibrahim IO, Izumi K, Goletz S, Boch K, Kalies K, Bieber K, Smith P, Schmidt E, Ludwig RJ. Ghorbanalipoor S, et al. Among authors: kamaguchi m. Front Immunol. 2022 Nov 30;13:1099535. doi: 10.3389/fimmu.2022.1099535. eCollection 2022. Front Immunol. 2022. PMID: 36532003 Free PMC article.
Bullous pemphigoid induced by IgG targeting type XVII collagen non-NC16A/NC15A extracellular domains is driven by Fc gamma receptor- and complement-mediated effector mechanisms and is ameliorated by neonatal Fc receptor blockade.
Pigors M, Patzelt S, Reichhelm N, Dworschak J, Khil'chenko S, Emtenani S, Bieber K, Hofrichter M, Kamaguchi M, Goletz S, Köhl G, Köhl J, Komorowski L, Probst C, Vanderheyden K, Balbino B, Ludwig RJ, Verheesen P, Schmidt E. Pigors M, et al. Among authors: kamaguchi m. J Pathol. 2024 Feb;262(2):161-174. doi: 10.1002/path.6220. Epub 2023 Nov 6. J Pathol. 2024. PMID: 37929639
29 results